Resumen: Biocytogen y Acepodia combinan fuerzas para desarrollar anticuerpos biespecíficos y ADC de carga doble para el tratamiento de tumores complejos

PEKÍN, ALAMEDA (California) y TAIPÉI–(BUSINESS WIRE)–Biocytogen (HKEX: 02315) y Acepodia (6976:TT) anunciaron hoy una alianza estratégica para evaluar de forma conjunta un programa de conjugados de anticuerpos-fármacos biespecíficos de carga doble (BsAD2C). Esta colaboración combina la plataforma RenLite® de Biocytogen con la tecnología de conjugación anticuerpo-fármaco doble (AD2C) de Acepodia para enfrentar algunos de los desafíos oncológicos más difíciles, como la heterogeneidad y la resis
Read More

Vir Biotechnology Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for Dual Masked T-Cell Engagers VIR-5818 in Solid Tumors and VIR-5500 in mCRPC

SAN FRANCISCO–(BUSINESS WIRE)–Vir Biotechnology, Inc. (Nasdaq: VIR) today is presenting initial Phase 1 data from two of its dual-masked T-cell engagers (TCEs): VIR-5818, targeting a variety of HER2-expressing solid tumors; and VIR-5500, targeting PSMA in metastatic castration-resistant prostate cancer (mCRPC). Data show encouraging preliminary safety and efficacy profiles with no dose-limiting cytokine release syndrome (CRS), maximum tolerated dose (MTD) not yet reached as dose escalation co
Read More

Cencora Announces Date and Time for First Quarter Fiscal 2025 Earnings Release

CONSHOHOCKEN, Pa.–(BUSINESS WIRE)–Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the First Quarter of Fiscal 2025 on Wednesday, February 5, 2025, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on February 5, 2025. Participating in the conference call will be: Robert P. Mauch, President & Chief Executive Officer James F. Cleary, Executive Vice President &
Read More

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOSTON–(BUSINESS WIRE)–Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the grant of stock options to purchase 15,000 shares of its common stock to one new employee. The awards were granted pursuant to the Nasdaq inducement grant exception as an inducement material to the employee’s acceptance of employment with Verastem Oncology in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options have
Read More

CorriXR Therapeutics Appoints Jan Case as Chief Operating Officer

NEWARK, Del.–(BUSINESS WIRE)– #CRISPR–CorriXR Therapeutics, Inc., a pioneering biotherapeutics company focused on oncology and innovative technologies to overcome drug resistance in solid tumors, announced that Jan Case has joined the Company as Chief Operating Officer. With over 25 years of experience in the biotechnology and pharmaceutical sectors, Case has driven operational excellence and strategic growth. As president of Cellicon Valley Consulting, she helped biotech start-ups, especially in the
Read More

Butterfly Network Reports Preliminary, Unaudited Fourth Quarter 2024 Revenue Growth of Approximately 35% Year over Year

BURLINGTON, Mass & NEW YORK–(BUSINESS WIRE)—- $BFLY #POCUS–Butterfly Network, Inc. (NYSE: BFLY) (“Butterfly”, “the Company”), a digital health company transforming care with portable, semiconductor-based ultrasound technology and intuitive software, today announced that it expects to report revenue growth for the fourth quarter ended December 31, 2024 of approximately 35% year over year. Joseph DeVivo, Butterfly’s President, Chief Executive Officer and Chairman commented, “The Butterfly team closed out 2024
Read More

Bruker Launches Infrared Imaging Microscope for Pharma and Life Science Research

BILLERICA, Mass.–(BUSINESS WIRE)—- $BRKR #BRKR–Bruker Corporation (Nasdaq: BRKR) today announced the launch of the LUMOS™ II ILIM, a quantum cascade laser (QCL) based infrared imaging microscope. The new LUMOS II ILIM redefines performance standards, enabling pharma and life science researchers to capture ultrafast IR images of expansive areas with enhanced spatial resolution. The LUMOS II ILIM features a patented coherence reduction method for infrared laser imaging essentially free from artifacts in both
Read More

KARL STORZ Acquires Medical Business of Visual Collaboration Software Company T1V

TUTTLINGEN, Germany–(BUSINESS WIRE)–The family-owned MedTech company KARL STORZ is pleased to announce the acquisition of the medical business of T1V, a US-based visual collaboration software company. KARL STORZ has had a longstanding partnership with T1V to build its existing CollaboratOR portfolio. This acquisition marks a significant step for KARL STORZ in shaping integrated hardware and software solutions for digital surgery in global operating rooms, complementing its state-of-the-art en
Read More

Biomarker and Trial Optimisation Needed to Drive R&D Progress in Alzheimer’s and Related Disorders – ICON Survey

DUBLIN–(BUSINESS WIRE)–ICON plc, (NASDAQ: ICLR) a world-leading clinical research organisation powered by healthcare intelligence, today released the findings of a survey of over 120 biotech and pharma professionals developing treatments for neurodegenerative disorders. The findings indicate that, despite recent successes in developing disease modifying treatments for Alzheimer’s, persistent challenges that remain in neurodegenerative clinical trials can be mitigated by underutilised trial me
Read More
Top